Differential effects of calmodulin and protein kinase C antagonists on bone resorption and acid transport activity.
Tamoxifen inhibits bone resorption by disrupting calmodulin-dependent processes. Since tamoxifen inhibits protein kinase C in other cells, we compared the effects of tamoxifen and the PKC inhibitor, bis indolylmaleimide II (bIM), on bone resorption and acid transport activity in isolated membrane vesicles. Bis indolylmaleimide inhibited bone resorption 50% with an IC50 approximately 3 microM, as well as acid transport activity in a concentration -dependent manner with an IC50 of approximately 0.4 IM. The IC50 of bIM for inhibiting acid transport activity was similar to that of calmodulin antagonists. The potassium ionophore, valinomycin, failed to restore bIM or tamoxifen-dependent inhibition of acid transport, suggesting that bIM and tamoxifen both inhibit H(+)-ATPase activity. Half maximal inhibitory concentrations of tamoxifen and bIM were not additive in acid transport assays, suggesting different sites of action. Furthermore, exogenous calmodulin blocked tamoxifen, but not bIM, -dependent inhibition of acid transport. We also compared the effects of tamoxifen and bIM on phosphorylation of proteins in isolated membrane fractions as determined by 32P incorporation and autoradiography. Tamoxifen had no effect on protein phosphorylation in contrast to bIM, which inhibited phosphorylation of eight proteins with different apparent kinetics. The data suggest that, while tamoxifen and bIM both affect H(+)-ATPase activity, the mechanisms of action are different.
Williams
J P
JP
Departament of Internal Medicine, University of Kentucky, Lexington, KY 40536, USA. jpwill2@uky.edu
Thames
A M
AM
McKenna
M A
MA
McDonald
J M
JM
D000165:Acridine Orange / Q000378:metabolism; D000818:Animals; D001862:Bone Resorption / Q000188:drug therapy* / Q000378:metabolism; D002147:Calmodulin / Q000494:pharmacology*; D002478:Cells, Cultured; D002645:Chickens; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D004965:Estrogen Antagonists / Q000494:pharmacology; D005260:Female; D007211:Indoles / Q000494:pharmacology; D020128:Inhibitory Concentration 50; D008301:Maleimides / Q000494:pharmacology; D010010:Osteoclasts / Q000187:drug effects* / Q000378:metabolism; D011493:Protein Kinase C / Q000037:antagonists & inhibitors*; D013629:Tamoxifen / Q000494:pharmacology; D022161:Transport Vesicles / Q000187:drug effects / Q000378:metabolism; D014634:Valinomycin / Q000494:pharmacology
D002147:Calmodulin; D004338:Drug Combinations; D004791:Enzyme Inhibitors; D004965:Estrogen Antagonists; D007211:Indoles; D008301:Maleimides; D013629:Tamoxifen; D014634:Valinomycin; D011493:Protein Kinase C; D000165:Acridine Orange; C088060:bisindolylmaleimide